Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The primary objective is to investigate in patients suffering from intermittent claudication
due to Fontaine stage II Peripheral Arterial Disease (PAD) whether a 26-week treatment by
HMR1766 on top of clopidogrel may result in an improvement of walking capacity, by comparing
three doses of HMR1766 to placebo, and calibrating such effect versus cilostazol.